News

Back to All News

Lake Street serves as qualified independent underwriter for Checkpoint Therapeutics, Inc. (NasdaqCM:CKPT) in its confidentially marketed public offering of 4,600,000 shares of common stock.

March 8, 2018

Lake Street is pleased to announce it served as the qualified independent underwriter for Checkpoint Therapeutics, Inc. (NasdaqCM:CKPT), a clinical-stage immuno-oncology biopharmaceutical company, in its confidentially marketed public offering of 4,600,000 shares of its common stock at a public offering price of $4.35 per share.
 

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint’s lead product candidate is a fully-human monoclonal antibody licensed from the Dana-Farber Cancer Institute that targets programmed death-ligand 1 (“PD-L1”). Checkpoint commenced a Phase 1 clinical study for its anti-PD-L1 antibody, CK-301, in October 2017, evaluating the safety and tolerability of CK-301 in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, and plans to develop CK-301 as a treatment for patients with non-small cell lung cancer (“NSCLC”) and other solid tumors. In addition, Checkpoint is developing a small-molecule, targeted anti-cancer agent, CK-101, for the treatment of patients with epidermal growth factor receptor (“EGFR”) mutation-positive NSCLC. In September 2016, Checkpoint commenced the Phase 1 portion of a Phase 1/2 clinical study for CK-101. Checkpoint’s pipeline also includes antibodies that target glucocorticoid-induced TNFR-related protein (“GITR”) and carbonic anhydrase IX (“CAIX”), in addition to oral, small-molecule, targeted anti-cancer agents that inhibit bromodomain and extra-terminal (“BET”) proteins and poly (ADP-ribose) polymerase (“PARP”). Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

Contact Us

Phone
612.326.1305

US Mail
920 Second Avenue South
Suite 700
Minneapolis, MN 55402

Email
Email Us

Find Us